Skip to main content
Reproductive Health logoLink to Reproductive Health
. 2024 Dec 4;21:179. doi: 10.1186/s12978-024-01913-y

HPV vaccine knowledge, attitude, and programme satisfaction among parents and caregivers of vaccine recipients in Ogun state Nigeria

Tope Olubodun 1,, Elijah Ayowole Ogunsola 2, Marcellina Olutomi Coker 3, Surajudeen Adekunle Olayinka 2, Waheed Àlàmú Elegbede 2, Joke Oluwatoyin Ojediran 4, Kofoworola B Olajide 2, Salimat Bola Sanni 2, Temitope Olawumi Oluwadare 2, Oluwaseun Temitope Inetagbo 4, Mobolanle Rasheedat Balogun 5, Onikepe Oluwadamilola Owolabi 6, Catherine Chidimma Anyadiegwu-Bello 4, Olukayode Abiodun Runsewe 2, Abiola Oluwatoyin Temitayo-Oboh 1,7, Tolulope Soyannwo 1, Oluwaseun Bisola Ogunsiji 4, Aduragbemi Banke-Thomas 8
PMCID: PMC11619644  PMID: 39633371

Abstract

Introduction

Human Papillomavirus is responsible for about 5% of the global cancer burden. In Nigeria, cervical cancer is the second most common cancer among women. The Federal Government of Nigeria and partners recently introduced Human Papillomavirus (HPV) vaccination into routine immunization beginning with 15 States and the Federal Capital Territory. This study assesses HPV vaccine knowledge, attitude and program satisfaction among parents and caregivers of vaccine recipients in Ogun State, Nigeria.

Methods

This is a cross-sectional study with sample size of 1012 respondents, carried out during the 5-day HPV immunization campaign in all 20 Local Government Areas in Ogun State, Nigeria. Data was collected using interviewer-administered questionnaires. Univariate analysis was done using frequency tables and bivariate analysis using Chi-square test. Multivariate analysis was carried out to identify the determinants of knowledge of HPV, knowledge of cervical cancer and programme satisfaction.

Results

All the respondents had heard of HPV vaccine and 67.5% had heard of cervical cancer. Eighty-two percent of the respondents heard of HPV vaccine for the first-time during the introduction programme. Eighty-two percent of respondents had good knowledge of HPV vaccine and 47.7% had good knowledge of cervical cancer. Forty-four percent of respondents heard about HPV vaccine via town/market announcers, 36.2% via radio, and 28.6% via social media. Common reasons respondents vaccinated their wards include, because there was a campaign (51.8%), to prevent cervical cancer (48.9%), and because it is free (38.3%). Twenty-nine percent were very satisfied with the HPV vaccination program and 63.2% were satisfied. All the respondents had positive attitude towards HPV vaccination, although 94.1% had heard messages discouraging people from vaccinating their wards. Respondents living in rural communities had higher odds of having good knowledge of HPV vaccine (aOR 2.232, 95% CI 1.527–3.263, p-value ≤ 0.001). Fathers with tertiary education were more likely to be satisfied with the programme (aOR 5.715, 95% CI 1.142–28.589, p-value = 0.034),

Conclusion

Knowledge of HPV vaccination was high and was informed by the HPV vaccination introduction programme. Use of outreaches, awareness drives, and provision of free vaccines should be intensified to further promote HPV vaccine uptake in Nigeria.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12978-024-01913-y.

Keywords: HPV vaccination, Knowledge, Attitude, Satisfaction, Cervical cancer, Nigeria

Plain language summary

Human Papillomavirus (HPV) vaccine was recently introduced into routine immunization in Nigeria, beginning with 15 States in the first phase. This study was carried out among 1012 parents/caregivers of adolescent girls who received the vaccine during the 5 days of the HPV immunization campaign in Ogun State, Nigeria. The study assessed the knowledge of HPV vaccine, attitude towards HPV vaccine and satisfaction with the HPV vaccination introduction programme among these parents/caregivers. Questions were asked using a questionnaire by interviewers. All the respondents had heard of HPV vaccine and majority heard about the vaccine, the first time during the vaccine introduction activities. Most of the respondents had good knowledge of HPV vaccine (82.4%) and 47.7% had good knowledge of cervical cancer. Common sources of information on the HPV vaccine were via town/market announcers, via radio, and via social media. All the respondents had positive attitude towards cervical cancer, even though 94.1% had heard messages discouraging parents from vaccinating their wards. Majority heard such discouraging messages via WhatsApp. Common reasons parents/caregivers vaccinated their wards were: because there was a campaign, to prevent cervical cancer, and because it is free. Majority of respondents were very satisfied with the HPV vaccination program. The HPV vaccination introduction programme contributed to high knowledge of HPV vaccine. Use of outreaches, awareness drives, and provision of free vaccines should be intensified to promote HPV vaccine uptake in Nigeria.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12978-024-01913-y.

Introduction

Human Papillomavirus (HPV) is considered the most common sexually transmitted viral infection worldwide. Globally, half of all malignancies that are related to infection are caused by HPV [1]. It is estimated that 4.5% of the global cancer burden (630,000 new cancer cases per year) is attributed to HPV infection [2]. Cervical cancer, anal cancer and oropharyngeal cancer are the most common HPV associated cancers. Unlike in high-income countries (HICs) where the incidence of cervical cancer is decreasing, there is a high incidence rate in low- and middle-income countries (LMICs) due to inadequate screening programmes [3]. Cervical cancer accounts for 22% of all female cancers in Africa [4] and is the second commonest cancer among women in Nigeria, with an age-standardized incidence rate (ASIR) of 18.4 per 100,000 and a high age-standardized mortality rate (ASMR) of 13.2 per 100,000. [5]

Primary prevention with HPV vaccination offers the best protection against HPV associated cancers [6]. Three HPV vaccines have been licenced for use—the bivalent vaccine which protects against HPV 16 and 18; the quadrivalent vaccine which protects against HPV 6, 11, 16, 18; and the nonavalent vaccine which protects against HPV 6, 11, 16, 18, 31, 33, 45, 52, 58 [6]. HPV vaccination was first licensed for use in 2006. The United States, Australia, Canada and the United Kingdom were among the first countries to introduce HPV vaccination into routine immunization programmes [7]. With the aid of the Vaccine Alliance (GAVI) funded projects and donation-based programs, by mid-2020, 56 LMICs had introduced HPV vaccination into routine immunization programmes [7].

Nigeria recently introduced the HPV vaccine into routine immunization [8, 9]. Prior to this, awareness of HPV vaccine was very low and it was only available to those who could afford to pay for it, in high-profile private hospitals and pharmacies, and some government hospitals. The introduction of the vaccination is in two phases. The first phase was conducted in 15 priority states and the Federal Capital Territory (FCT), and the next phase will include all other states. The Phase 1 vaccination introduction programme involved a set of pre-implementation planning and awareness generation activities, followed by a five-day vaccination campaign which began on the 24th of October 2023. The one-dose vaccination with Gardasil vaccine was for girls aged 9–14 years and was carried out using outreach approaches in schools and communities, and also in health facilities, during the campaign. After the campaign, the vaccination was limited to health facilities as it is being included in routine immunization schedule [8, 9].

Despite the successes recorded by many LMICs in the introduction of the HPV vaccine, there are still considerable challenges including weak social mobilization, vaccine hesitancy among parents, inadequate financing and health worker training, and problems with logistics [1012]. Getting feedback from parents and caregivers of vaccine recipients can help understand what is being done right and what can be improved upon. It is imperative to understand parents’ knowledge of the HPV vaccine, as this may influence uptake. Attitude towards the vaccine and parent’s satisfaction with the programme, can further inform implementation in Phase 1, and guide planning for the second phase. This study therefore aims to assess HPV vaccine knowledge, attitude and program satisfaction among parents and caregivers of vaccine recipients in Ogun State, Nigeria.

Methods

Study setting

Ogun State is located in southwest Nigeria. The language of the majority is Yoruba with scores of dialects. Abeokuta is the most populous city of Ogun State and is the State’s capital. Ogun State has 20 Local Government Areas (LGAs) and 236 wards. A total of 280,489 girls out of 500,465 targeted population of girls aged 9 to 14 were vaccinated against HPV during the campaign in Ogun State, Nigeria in October 2023 [13].

Study design and study population

This is an analytical cross-sectional study. The inclusion criteria for respondents was that they be parents and/or caregivers of vaccine recipients who have been living with the vaccine recipient for at least two years. Data collection was carried out during the five-day HPV vaccination campaign from 24th October 2023 to 28th October 2023 and parents/caregivers were recruited at the vaccination sites.

Sample size calculation

The minimum sample size was calculated using the Cochran formulae for descriptive studies n = Z2 pq/ d2 [14] (Where n = minimum sample size required, Z = standard normal deviate at 95% confidence interval = 1.96, p = proportion of the desired attribute from a previous study, q = 1- p, and d = acceptable error margin = 5%) The sample size was calculated with different p values: awareness of HPV vaccine; awareness of cervical cancer; knowledge of cervical cancer; and attitude towards cervical cancer, all from similar studies in southwest Nigeria. The p that gave the highest sample size was used (i.e. awareness of cervical cancer from a study in Lagos State, southwest Nigeria = 53.5 [15]). Minimum sample size calculated was 382. Due to the multistage sampling applied, the sample size was multiplied by 2.5 to adjust for design effect, and a sample size of 955 was obtained. Compensating for non-response of 10%, sample size came to 1061. After data collection and data cleaning, there were 1012 correctly filled questionnaires which were analysed.

Sampling

Multi-stage sampling was applied. All 20 LGAs were included in the study. In the first stage, ten wards were selected in each LGA via simple random sampling by balloting. In the second stage, five settlements were selected from each ward using simple random sampling by balloting and in the third stage, one respondent that met the inclusion criteria was selected from one vaccination site randomly in each of the selected settlements.

Data collection

Data was collected using pretested interviewer-administered questionnaires. Questions were derived from tools used in similar studies [1620] and included questions on socio-demographic characteristics of respondents, knowledge of HPV vaccination, knowledge of cervical cancer, attitude towards HPV vaccination, attitude towards cervical cancer, and satisfaction with the HPV immunization programme. Questionnaires were administered by trained research assistants using the Open Data Kit (ODK) mobile application. The research assistants used in this study were the State Technical Facilitators, the independent monitors and LGA monitoring team. They were trained to administer the questionnaires correctly and to ensure adherence with ethical considerations.

Data analysis

Data cleaning was done in Microsoft Excel 365. Descriptive analysis was carried out using frequency tables. Chi-Square test was used to compare attributes across urban and rural wards.

Knowledge of HPV vaccine was assessed with three questions—benefit of HPV vaccination, number of doses of HPV vaccination required and eligibility for HPV vaccination. The maximum score attainable was 3 and minimum score attainable was 0. This was converted to percentage and scores of ≥ 50% were classified as good knowledge, while scores < 50% were classified as poor knowledge.

Knowledge of cervical cancer was assessed using three questions—knowledge of symptoms of cervical cancer, knowledge of risk factors of cervical cancer, and having heard of cervical cancer screening. A respondent scores one full mark if he/she can mention two correct symptoms of cervical cancer, 0.5 marks if he/she mentions only one correct symptom and 0 marks if he/she mentions no correct symptom. Similar scoring was used for mention of risk factors of cervical cancer. A respondent scored one mark if he/she was aware of cervical cancer screening and 0 marks if he/she was not aware. The maximum attainable score for knowledge of cervical cancer was 3. This was also converted to percentage and scores of ≥ 50% were classified as good knowledge, and scores < 50% were classified as poor knowledge.

Attitude towards cervical cancer was assessed using five statements on a 5-point Likert scale, and attitude towards HPV vaccination was assessed using seven statements on a 5-point Likert scale. Total scores were calculated and scores at or above the median were considered as positive attitude.

Programme satisfaction was assessed with four questions—confidence in the competence of the vaccinators, confidence in the cleanliness/hygiene of the vaccination procedure, how respondent feels about adequacy of social mobilization and communication activities, and overall satisfaction with the programme.

Variables significantly associated with knowledge of HPV vaccine, knowledge of cervical cancer and overall satisfaction with the programme at bivariate analysis (Chi-Square) with p-value less than 0.05 were imputed into the multivariate model. Binary logistic regression was used to determine the predictors of knowledge of HPV vaccine, knowledge of cervical cancer and overall satisfaction with the programme. Level of statistical significance was set at p ≤ 0.05.

Data was analysed with Stata 17 (StataCorp LLC, College Station, TX, USA).

Ethical considerations

Ethical approval was obtained from Ogun State Health Research Ethical Review Committee (Approval Number: OGHREC/467/190). Written informed consent was obtained from all participants. All data from the study were handled with confidentiality.

Results

Over a third of respondents (36.1%) were between ages 41 and 50 years. Most of them were female (90.5%), married /co-habiting (78.6%), of Yoruba ethnicity (89%), and Christian (64.5%). Four in ten of the vaccine recipients (42.9%) were aged 8 and 10 years. Most of the respondents were parents of the vaccine recipient (87%). Nine out of ten times (88.7%), a parent made the decision to vaccinate the child. In the urban communities 42% of fathers had tertiary education while in the rural communities, 31.1% of fathers had tertiary education and the difference was statistically significant (Urban 42%, Rural 31.1%, p < 0.001). In urban communities, 34.7% of mothers had tertiary education while in the rural communities, 26.6% of mothers had tertiary education (Urban 34.7%, Rural 26.6%, p = 0.003) (Table 1).

Table 1.

Description of select characteristics

Variables Total sample Urban Rural p-value
Freq 
(%)
(n = 1012) Freq (%) Freq (%)
(n = 473) (n = 539)
Age of respondent (years)
 20–30 99 9.8 34 (7.2%) 65 (12.1%) 0.042
 31–40 415 41 197 (41.6%) 218 (40.4%)
 41–50 365 36.1 183 (38.7%) 182 (33.8%)
 61–72 133 13.1 59 (12.5%) 74 (13.7%)
Sex of respondent
 Female 916 90.5 432 (91.3%) 484 (89.8%) 0.405
 Male 96 9.5 41 (8.7%) 55 (10.2%)
Marital status
 Single 121 12 45 (9.5%) 76 (14.1%) 0.005
 Married/Cohabiting 795 78.6 369 (78%) 426 (79%)
 Divorced/Separated 59 5.8 37 (7.8%) 22 (4.1%)
 Widowed 37 3.7 22 (4.7%) 15 (2.8%)
Ethnicity
 Yoruba 901 89 421 (89%) 480 (89.1%) 0.001
 Ibo 50 4.9 35 (7.4%) 15 (2.8%)
 Hausa 20 2 8 (1.7%) 12 (2.2%)
 Others 41 4.1 9 (1.9%) 32 (5.9%)
Religion
 Christianity 653 64.5 302 (63.8%) 351 (65.1%) 0.276
 Islam 332 32.8 162 (34.2%) 170 (31.5%)
 Traditional 27 2.7 9 (1.9%) 18 (3.3%)
Age of VR (years)
 8–10 434 42.9 217 (45.9%) 217 (40.3%) 0.188
 11–12 339 33.5 152 (32.1%) 187 (34.7%)
 13–20 239 23.6 104 (22%) 135 (25%)
Respondent’s relationship with VR
 Parent 880 87 413 (87.3%) 467 (86.6%) 0.483
 Sibling 27 2.7 11 (2.3%) 16 (3%)
 Grandparent 31 3.1 14 (3%) 17 (3.2%)
 Other relative 30 3 18 (3.8%) 12 (2.2%)
 Neighbour/Friend 11 1.1 3 (0.6%) 8 (1.5%)
 Other guardian 33 3.3 14 (3%) 19 (3.5%)
Father of VR level of education*
 No formal 95 9.8 31 (7%) 64 (12.2%) 0.001
 Primary 109 11.3 37 (8.4%) 72 (13.7%)
 Secondary 413 42.8 188 (42.6%) 225 (42.9%)
 Tertiary 348 36.1 185 (42%) 163 (31.1%)
Mother of VR level of education*
 No formal 93 9.4 32 (7%) 61 (11.5%) 0.003
 Primary 153 15.5 60 (13.1%) 93 (17.5%)
 Secondary 442 44.7 207 (45.2%) 235 (44.3%)
 Tertiary 300 30.4 159 (34.7%) 141 (26.6%)
Father of VR occupation*
 Unemployed 64 6.5 18 (3.9%) 46 (8.7%) 0.011
 Unskilled 361 36.5 162 (35.3%) 199 (37.5%)
 Semiskilled 471 47.6 231 (50.3%) 240 (45.2%)
 Skilled 94 9.5 48 (10.5%) 46 (8.7%)
Mother of VR occupation*
 Unemployed 82 8.2 35 (7.4%) 47 (8.9%) 0.713
 Unskilled 460 45.9 217 (46%) 243 (45.8%)
 Semiskilled 385 38.4 181 (38.3%) 204 (38.5%)
 Skilled 75 7.5 39 (8.3%) 36 (6.8%)
Person who made the decision to vaccinate childm
 Parent 898 88.7 416 (87.9%) 482 (89.4%) 0.459
 Elder sibling 37 3.7 12 (2.5%) 25 (4.6%) 0.076
 Grandparent 56 5.5 28 (5.9%) 28 (5.2%) 0.615
 Other relative 46 4.5 21 (4.4%) 25 (4.6%) 0.880
 Other guardian 45 4.4 20 (4.2%) 25 (4.6%) 0.752
 Neighbour/Friend 42 4.2 17 (3.6%) 25 (4.6%) 0.406

Bold p-values indicate statistical significance

*Has missing variables VR—vaccine recipient mMultiple response allowed

Most of the respondents heard of HPV vaccine, the first time, during the vaccine introduction activities (82.6%) and, most also heard of cervical cancer for the first time, during the vaccine introduction activities (55.4%). Majority of respondents heard of HPV vaccination via town announcers/market announcers. In rural communities, 52.5% of respondents heard via town announcers/market announcers while in urban communities, 35.5% (Urban 35.5%, Rural 52.5%, p < 0.001) heard via this means. Forty-one percent of urban dwellers heard via radio, while 31.9% of rural dwellers heard via radio (Urban 41%, Rural 31.9%, p = 0.003). Other common sources of information were social media (Urban 29.4%, Rural 27.8%, p = 0.584) and Banners/posters/handbills (Urban 22.8%, Rural 29.1%, p = 0.023). Proportion of respondents with good knowledge of HPV vaccine were higher in rural communities than in urban communities (Urban 77.4%, Rural 86.8%, p < 0.001). There was no statistically significant difference in proportion of respondents with good knowledge of cervical cancer across urban and rural communities (Urban 45.2%, Rural 49.9%, p = 0.148) (Table 2).

Table 2.

Knowledge of HPV vaccine and cervical cancer among respondents

Variables Total Sample Urban Rural p-value
Freq
%
(n = 1012) Freq (%) Freq (%)
(n = 473) (n = 539)
Heard of HPV vaccine
 Yes 1012 100 473 (100%) 539 (100%)
First time respondent heard of HPV vaccine was during the HPV vaccine introduction programme
 Yes 836 82.6 389 (82.2%) 447 (82.9%) 0.773
 No 176 17.4 84 (17.8%) 92 (17.1%)
Source of information on HPV vaccinem
Town announcer/market announcer 451 44.6 168 (35.5%) 283 (52.5%) 0.001
Radio 366 36.2 194 (41%) 172 (31.9%) 0.003
Social media 289 28.6 139 (29.4%) 150 (27.8%) 0.584
Banners/posters/handbills 265 26.2 108 (22.8%) 157 (29.1%) 0.023
Hospital/health center 237 23.4 103 (21.8%) 134 (24.9%) 0.248
Friends 178 17.6 90 (19%) 88 (16.3%) 0.260
Television 152 15 76 (16.1%) 76 (14.1%) 0.382
Community leader 140 13.8 44 (9.3%) 96 (17.8%) 0.001
Relatives 128 12.6 65 (13.7%) 63 (11.7%) 0.327
WDC meeting/advocacy meeting 49 4.8 25 (5.3%) 24 (4.5%) 0.538
Newspaper/magazine 42 4.2 15 (3.2%) 27 (5%) 0.144
Church/pastor 31 3.1 13 (2.7%) 18 (3.3%) 0.586
School lecture 30 3 19 (4%) 11 (2%) 0.064
Mosque/Imam 14 1.4 5 (1.1%) 9 (1.7%) 0.405
Book 3 0.3 1 (0.2%) 2 (0.4%) 0.641
Benefit of HPV vaccine
Prevents cervical cancer/cancers 853 84.3 398 (84.1%) 455 (84.4%) 0.035
Others 17 1.7 3 (0.6%) 14 (2.6%)
Don’t know 142 14 72 (15.2%) 70 (13%)
Doses of HPV vaccine required
 1 688 68 299 (63.2%) 389 (72.2%) 0.001
 2 60 5.9 23 (4.9%) 37 (6.9%)
 3 18 1.8 3 (0.6%) 15 (2.8%)
 4 246 24.3 148 (31.3%) 98 (18.2%)
Who is to take HPV vaccine
 Babies 3 0.3 2 (0.4%) 1 (0.2%) 0.001
 Young girls, any age 92 9.1 64 (13.5%) 28 (5.2%)
 Girls aged 9 to 14 years 833 82.3 357 (75.5%) 476 (88.3%)
 Adult women 10 1 10 (2.1%) 0 (0%)
 Not yet sexually active 27 2.7 13 (2.7%) 14 (2.6%)
 Sexually active girls and women 12 1.2 10 (2.1%) 2 (0.4%)
 Women HPV positive 4 0.4 2 (0.4%) 2 (0.4%)
 None of above 7 0.7 3 (0.6%) 4 (0.7%)
 Don’t know 24 2.4 12 (2.5%) 12 (2.2%)
Heard of cervical cancer
 Yes 630 67.5 280 (64.5%) 350 (70.1%) 0.105
 No 274 29.4 142 (32.7%) 132 (26.5%)
 Don’t know 29 3.1 12 (2.8%) 17 (3.4%)
Heard of cervical cancer for the first time, during the HPV vaccine introduction programme
 Yes 349 55.4 139 (49.6%) 210 (60%) 0.009
 No 281 44.6 141 (50.4%) 140 (40%)
Symptoms of cervical cancer knownm
 Foul smelling vaginal discharge 303 48.1 135 (48.2%) 168 (48%) 0.957
 Heavy vaginal bleeding 238 37.8 91 (32.5%) 147 (42%) 0.015
 Vaginal bleeding between periods 193 30.6 57 (20.4%) 136 (38.9%) 0.001
 Vaginal bleeding after intercourse 162 25.7 48 (17.1%) 114 (32.6%) 0.001
 Vaginal bleeding after menopause 85 13.5 21 (7.5%) 64 (18.3%) 0.001
 Lower abdominal pain 121 19.2 71 (25.4%) 50 (14.3%) 0.001
 Weight loss 117 18.6 61 (21.8%) 56 (16%) 0.064
 Don’t know 147 23.3 75 (26.8%) 72 (20.6%) 0.067
Risk factors of cervical cancer knownm
 Early age at first sex 270 42.9 109 (38.9%) 161 (46%) 0.075
 Early age at first pregnancy 105 16.7 26 (9.3%) 79 (22.6%) 0.001
 Many sexual partners 252 40 107 (38.2%) 145 (41.4%) 0.413
 Partner with many partners 232 36.8 92 (32.9%) 140 (40%) 0.065
 Many pregnancies 27 4.3 6 (2.1%) 21 (6%) 0.018
 Use of tobacco 31 4.9 16 (5.7%) 15 (4.3%) 0.410
 Infection with HPV 169 26.8 76 (27.1%) 93 (26.6%) 0.872
 Poor hygiene 83 13.2 38 (13.6%) 45 (12.9%) 0.792
 Sin against God 6 1 4 (1.4%) 2 (0.6%) 0.271
 Fate/destiny 8 1.3 4 (1.4%) 4 (1.1%) 0.750
 Hereditary 19 3 9 (3.2%) 10 (2.9%) 0.795
 Prolonged use of oral contraceptives 15 2.4 4 (1.4%) 11 (3.1%) 0.161
 Low immunity 46 7.3 27 (9.6%) 19 (5.4%) 0.043
 Don’t know 108 17.1 49 (17.5%) 59 (16.9%) 0.832
Heard of cervical cancer screening
 Yes 342 54.3 162 (57.9%) 180 (51.4%) 0.127
 No 248 39.4 98 (35%) 150 (42.9%)
 Don’t know 40 6.3 20 (7.1%) 20 (5.7%)
Level of HPV vaccine knowledge
 Poor knowledge 178 17.6 107 (22.6%) 71 (13.2%) 0.001
 Good knowledge 834 82.4 366 (77.4%) 468 (86.8%)
Level of cervical cancer knowledge
 Poor knowledge 488 52.3 238 (54.8%) 250 (50.1%) 0.148
 Good knowledge 445 47.7 196 (45.2%) 249 (49.9%)

Bold p-values indicate statistical significance

mMultiple response allowed

In urban and rural communities, 49.0% and 49.9% agreed respectively, that cervical cancer is a severe disease (p = 0.320). In urban and rural communities, 12.5% and 12.1% agreed respectively, that cervical cancer cannot be prevented, but is rather attributed to fate (p = 0.511). In urban and rural communities respectively, 35.5% and 35.3% agreed that they had concerns about the safety of HPV vaccine (p = 0.018). Also, 20.1% of respondents in urban communities and 22.8% in rural communities agreed they had doubts about the effectiveness of the vaccine (p = 0.036). Fifty-nine percent of urban dwellers and 53.4% of rural dwellers however agreed that they are likely to recommend HPV vaccination to others (p = 0.034). All the respondents had positive attitude towards cervical cancer and HPV vaccine (Table 3).

Table 3.

Attitude towards cervical cancer and HPV vaccine

Attitudinal statements Total Sample Urban Rural p-value
Freq
%
(n = 1012) Freq (%) Freq (%)
(n = 473) (n = 539)
Cervical cancer is a severe disease
 Strongly agree 281 27.8 127 (26.8%) 154 (28.6%) 0.320
 Agree 501 49.5 232 (49%) 269 (49.9%)
 Neutral 164 16.2 85 (18%) 79 (14.7%)
 Disagree 39 3.9 14 (3%) 25 (4.6%)
 Strongly disagree 27 2.7 15 (3.2%) 12 (2.2%)
I/my spouse are not susceptible to cervical cancer
 Strongly agree 105 10.4 41 (8.7%) 64 (11.9%) 0.095
 Agree 275 27.2 129 (27.3%) 146 (27.1%)
 Neutral 251 24.8 134 (28.3%) 117 (21.7%)
 Disagree 297 29.3 133 (28.1%) 164 (30.4%)
 Strongly disagree 84 8.3 36 (7.6%) 48 (8.9%)
I/my spouse cannot have cervical cancer because we have spiritual protection
 Strongly agree 94 9.3 38 (8%) 56 (10.4%) 0.299
 Agree 203 20.1 90 (19%) 113 (21%)
 Neutral 204 20.2 107 (22.6%) 97 (18%)
 Disagree 402 39.7 185 (39.1%) 217 (40.3%)
 Strongly disagree 109 10.8 53 (11.2%) 56 (10.4%)
I/my spouse cannot have cervical cancer because we are not promiscuous
 Strongly agree 91 9 37 (7.8%) 54 (10%) 0.048
 Agree 283 28 143 (30.2%) 140 (26%)
 Neutral 204 20.2 105 (22.2%) 99 (18.4%)
 Disagree 359 35.5 149 (31.5%) 210 (39%)
 Strongly disagree 75 7.4 39 (8.2%) 36 (6.7%)
Cervical cancer cannot be prevented. It is a matter of fate
 Strongly agree 44 4.3 15 (3.2%) 29 (5.4%) 0.511
 Agree 124 12.3 59 (12.5%) 65 (12.1%)
 Neutral 219 21.6 105 (22.2%) 114 (21.2%)
 Disagree 461 45.6 214 (45.2%) 247 (45.8%)
 Strongly disagree 164 16.2 80 (16.9%) 84 (15.6%)
I have fears about the safety of HPV vaccine
 Strongly agree 44 4.3 10 (2.1%) 34 (6.3%) 0.018
 Agree 358 35.4 168 (35.5%) 190 (35.3%)
 Neutral 216 21.3 109 (23%) 107 (19.9%)
 Disagree 301 29.7 145 (30.7%) 156 (28.9%)
 Strongly disagree 93 9.2 41 (8.7%) 52 (9.6%)
I have doubts about the effectiveness of HPV vaccine
 Strongly agree 41 4.1 16 (3.4%) 25 (4.6%) 0.036
 Agree 218 21.5 95 (20.1%) 123 (22.8%)
 Neutral 248 24.5 129 (27.3%) 119 (22.1%)
 Disagree 404 39.9 197 (41.6%) 207 (38.4%)
 Strongly disagree 101 10 36 (7.6%) 65 (12.1%)
HPV vaccination can make girls promiscuous/start having sex early
 Strongly agree 14 1.4 4 (0.8%) 10 (1.9%) 0.694
 Agree 92 9.1 41 (8.7%) 51 (9.5%)
 Neutral 180 17.8 87 (18.4%) 93 (17.3%)
 Disagree 511 50.5 240 (50.7%) 271 (50.3%)
 Strongly disagree 215 21.2 101 (21.4%) 114 (21.2%)
I fear that HPV vaccination can make girls infertile
 Strongly agree 27 2.7 10 (2.1%) 17 (3.2%) 0.455
 Agree 130 12.8 63 (13.3%) 67 (12.4%)
 Neutral 192 19 87 (18.4%) 105 (19.5%)
 Disagree 449 44.4 221 (46.7%) 228 (42.3%)
 Strongly disagree 214 21.1 92 (19.5%) 122 (22.6%)
I have concerns about the minor side effects of HPV vaccine e.g. injection site pain, fever
 Strongly agree 57 5.6 16 (3.4%) 41 (7.6%) 0.020
 Agree 427 42.2 209 (44.2%) 218 (40.4%)
 Neutral 216 21.3 110 (23.3%) 106 (19.7%)
 Disagree 226 22.3 103 (21.8%) 123 (22.8%)
 Strongly disagree 86 8.5 35 (7.4%) 51 (9.5%)
I fear HPV vaccine may be harmful to health
 Strongly agree 24 2.4 6 (1.3%) 18 (3.3%) 0.158
 Agree 150 14.8 70 (14.8%) 80 (14.8%)
 Neutral 232 22.9 118 (24.9%) 114 (21.2%)
 Disagree 469 46.3 219 (46.3%) 250 (46.4%)
 Strongly disagree 137 13.5 60 (12.7%) 77 (14.3%)
I am likely to recommend HPV vaccination to others
 Strongly agree 158 15.6 71 (15%) 87 (16.1%) 0.034
 Agree 569 56.2 281 (59.4%) 288 (53.4%)
 Neutral 191 18.9 91 (19.2%) 100 (18.6%)
 Disagree 72 7.1 24 (5.1%) 48 (8.9%)
 Strongly disagree 22 2.2 6 (1.3%) 16 (3%)
Attitude towards cervical cancer
 Positive attitude 1012 100 473 (100%) 539 (100%)
Attitude towards HPV vaccine
 Positive attitude 1012 100 473 (100%) 539 (100%)

Bold p-values indicate statistical significance

The commonest reasons for vaccinating wards include: To prevent cervical cancer (48.9%), because there is an ongoing campaign (48.2%), because it is free (38.3%), I heard about it and felt I should bring my ward (25.9%), and a health worker advised for it (18.3%) (Table 4).

Table 4.

Respondents’ reasons for vaccinating wards

Reasons for vaccinating wardm Total Sample Urban Rural p-value
Freq
%
(n = 1012) Freq (%) Freq (%)
(n = 473) (n = 539)
To prevent cervical cancer 495 48.9 220 (46.5%) 268 (49.7%) 0.308
Because there is an ongoing campaign 488 48.2 74 (15.6%) 98 (18.2%) 0.284
Because it is free 388 38.3 184 (38.9%) 204 (37.8%) 0.731
I heard about it and felt I should bring my ward 262 25.9 112 (23.7%) 150 (27.8%) 0.133
A health worker advised for it 185 18.3 48 (10.1%) 89 (16.5%) 0.003
Social mobilization activities encouraged me to vaccinate my ward 172 17 228 (48.2%) 267 (49.5%) 0.672
I saw others vaccinating their wards 137 13.5 16 (3.4%) 10 (1.9%) 0.125
Due to community leader’s advice 54 5.3 23 (4.9%) 31 (5.8%) 0.530
Due to friend’s advice 42 4.2 5 (1.1%) 6 (1.1%) 0.932
Due to family member’s advice 39 3.9 22 (4.7%) 17 (3.2%) 0.217
Due to religious leader’s advice 26 2.6 96 (20.3%) 89 (16.5%) 0.120
Due to traditional leader’s advice 11 1.1 25 (5.3%) 17 (3.2%) 0.090
No reason 3 0.3 2 (0.4%) 5 (0.9%) 0.334

Bold p-value indicates statistical significance

mMultiple response allowed

Seventy percent of the respondents were confident in the competence of the vaccinator, 74.9% were confident in the cleanliness of procedures, 52.9% perceived social mobilization efforts as adequate and 35.0% as somewhat adequate. Sixty-three percent were satisfied with the overall programme and 29.4% were very satisfied. There was no statistically significant difference in confidence in competence of vaccinator, cleanliness of the procedures and perception of social mobilization activities between urban and rural dwellers (p < 0.05). However, regarding overall programme satisfaction, a higher proportion of rural dwellers (34.0%) were very satisfied, compared to urban dwellers (24.3%) (X2 = 13.5221 p = 0.001) (Table 5).

Table 5.

Program satisfaction among respondents

Variables Total Sample Urban Rural p-value
Freq
(%)
(n = 1012) Freq (%) Freq (%)
(n = 473) (n = 539)
Confidence in competence of vaccinator
 Confident 717 70.8 329 (69.6%) 388 (72%) 0.313
 Somewhat confident 283 28 136 (28.8%) 147 (27.3%)
 Not confident 12 1.2 8 (1.7%) 4 (0.7%)
Confidence in the cleanliness of procedures
 Confident 758 74.9 353 (74.6%) 405 (75.1%) 0.881
 Somewhat confident 244 24.1 116 (24.5%) 128 (23.7%)
 Not confident 10 1 4 (0.8%) 6 (1.1%)
Perception of social mobilization
 Adequate 535 52.9 243 (51.4%) 292 (54.2%) 0.128
 Somewhat adequate 354 35 162 (34.2%) 192 (35.6%)
 Not adequate 123 12.2 68 (14.4%) 55 (10.2%)
Overall satisfaction of programme
 Very satisfied 298 29.4 115 (24.3%) 183 (34%) 0.001
 Satisfied 640 63.2 327 (69.1%) 313 (58.1%)
 Not satisfied 74 7.3 31 (6.6%) 43 (8%)

Bold p-value indicates statistical significance

Majority (94.1%) had heard messages discouraging parents from vaccinating their wards. Sixty-four percent of the respondents heard such messages from WhatsApp, 53.0% heard such messages from a friend/relative and 31.7% heard such messages from a community member. A higher proportion of urban dwellers heard such messages via WhatsApp (Urban 68.3%, Rural 60.9% X2 = 6.0673 p = 0.014). A higher proportion of rural dwellers heard such messages from friend/relative (Urban 49.3%, Rural 56.2%, X2 = 4.8919 p = 0.027) and from a community member (Urban 26.4%, Rural 36.4% X2 = 11.4847 p = 0.001) (Table 6).

Table 6.

Source of discouraging messages on HPV vaccination

Variables Total Sample Urban Rural p-value
Freq
(%)
(n = 1012) Freq (%) Freq (%)
(n = 473) (n = 539)
Heard message discouraging parents from vaccinating their wards
 Yes 952 94.1 448 (94.7%) 504 (93.5%) 0.417
 No 60 5.9 25 (5.3%) 35 (6.5%)
Source of such messagesm
 WhatsApp 651 64.3 323 (68.3%) 328 (60.9%) 0.014
 Friend/relative 536 53 233 (49.3%) 303 (56.2%) 0.027
 Community member 321 31.7 125 (26.4%) 196 (36.4%) 0.001
 Church 63 6.2 22 (4.7%) 41 (7.6%) 0.052
 Traditional leader 54 5.3 21 (4.4%) 33 (6.1%) 0.235
 Others 50 4.9 23 (4.9%) 27 (5%) 0.914
 Mosque 42 4.2 18 (3.8%) 24 (4.5%) 0.607
 Did not hear any discouraging message 49 4.8 21 (4.4%) 28 (5.2%) 0.577

Bold p-values indicate statistical significance

mMultiple response allowed

Father’s level of education, mother’s occupation, religion and place of residence were predictors of good knowledge of HPV vaccine. Fathers with tertiary education were three times more likely to have good knowledge of HPV vaccine, compared to those with no formal education (aOR 3.194, 95% CI 1.119–9.113, p-value = 0.03) Mothers with skilled employment were also three times more likely to have good HPV vaccine knowledge than the unemployed (aOR 3.841, 95% CI 1.053–14.014, p-value = 0.042). Respondents that practiced traditional religion were less likely to have good HPV vaccine knowledge and respondents who lived in rural communities had two times higher odds of having good knowledge of HPV vaccine (aOR 2.232, 95% CI 1.527–3.263, p-value ≤ 0.001) (Table 7). Relationship with vaccine recipient, father’s level of education, mother’s occupation, were predictors of good knowledge of cervical cancer (Table 7).

Table 7.

Logistic regression of Knowledge of HPV vaccine and cervical cancer

Variables aOR 95% CI (Lower limit) 95% CI (Upper limit) p-value
Knowledge of HPV vaccine
Age of respondent
 20–30 1
 31–40 0.471 0.22 1.008 0.052
 41–50 1.041 0.0468 2.315 0.921
 61–72 0.391 0.166 0.922 0.032
Sex
 Male 1
 Female 1.295 0.713 2.354 0.395
Marital status
 Single 1
 Married/Cohabiting 0.524 0.27 1.019 0.057
 Divorced/Separated .9 0.316 2.565 0.844
 Widowed 0.368 0.124 1.089 0.071
Ethnicity
 Yoruba 1
 Ibo 0.549 0.247 1.217 0.14
 Hausa 1.663 0.4 6.915 0.048
 Others 0.517 0.216 1.235 0.138
Fathers level of education
 No education 1
 Primary 3.455 1.302 9.167 0.013
 Secondary 1.786 0.73 4.369 0.204
 Tertiary 3.194 1.119 9.113 0.03
Mothers level of education
 No education 1
 Primary 0.787 0.318 1.944 0.603
 Secondary 1.098 0.428 2.82 0.845
 Tertiary 1.216 0.401 3.688 0.73
Fathers occupation
 Unemployed 1
 Unskilled 0.991 0.408 2.412 0.985
 Semiskilled 0.663 0.266 1.653 0.378
 Skilled 0.78 0.245 2.481 0.674
Mothers occupation
 Unemployed 1
 Unskilled 1.469 0.721 2.991 0.289
 Semiskilled 1.149 0.532 2.482 0.724
 Skilled 3.841 1.053 14.014 0.042
Religion
 Christianity 1
 Islam 0.724 0.487 1.076 0.11
 Traditional 0.279 0.101 0.771 0.014
Place of residence
 Urban 1
 Rural 2.232 1.527 3.263 < 0.001
Knowledge of cervical cancer
Relationship with VR
 Parent 1
 Sibling 1.152 0.5 2.653 0.74
 Grandparent 2.393 1.035 5.537 0.041
 Other relative 1.016 0.443 2.328 0.97
 Neighbour/Friend 3.298 0.631 17.235 0.157
 Other guardian 4.99 1.661 14.992 0.004
Fathers level of education
 No education 1
 Primary 0.655 0.291 1.474 0.307
 Secondary 0.975 0.445 2.135 0.95
 Tertiary 2.472 1.035 5.905 0.042
Mothers level of education
 No education 1
 Primary 1.479 0.678 3.224 0.325
 Secondary 0.803 0.364 1.774 0.588
 Tertiary 0.595 0.246 1.442 0.25
Fathers occupation
 Unemployed 1
 Unskilled 1.016 0.528 1.953 0.963
 Semiskilled 0.723 0.369 1.418 0.345
 Skilled 0.94 0.413 2.144 0.884
Mothers occupation
 Unemployed 1
 Unskilled 1.25 0.692 2.256 0.46
 Semiskilled 1.169 0.623 2.193 0.626
 Skilled 3.087 1.307 7.291 0.01
Place of residence
 Urban 1
 Rural 1.195 0.901 1.585 0.216

Bold p-values indicate statistical significance

Marital status, father’s level of education, father’s occupation, and religion were predictors of satisfaction with the HPV vaccination programme. Divorced/separated and widowed respondents were less likely to be satisfied with the programme. In cases where the wards fathers had tertiary education, the respondent was more likely to be satisfied with the programme (aOR 5.715, 95% CI 1.142–28.589, p-value = 0.034), and in cases where the wards fathers were employed, the respondents were more likely to be satisfied with the programme (Table 8).

Table 8.

Logistic regression of overall programme satisfaction

Variables aOR 95% CI (Lower limit) 95% CI (Upper limit) p-value
Age of respondent
 20–30 1
 31–40 0.312 0.071 1.372 0.123
 41–50 0.305 0.069 1.36 0.12
 61–72 3.649 0.42 31.726 0.241
Sex
 Female 1
 Male 0.633 0.275 1.457 0.282
Marital status
 Single 1
 Married/Cohabiting 0.27 0.068 1.075 0.063
 Divorced/Separated 0.14 0.028 0.707 0.017
 Widowed 0.064 0.01 0.404 0.003
Ethnicity
 Yoruba 1
 Ibo 0.983 0.245 3.95 0.981
 Hausa 0.319 0.083 1.226 0.096
 Others 0.495 0.16 1.534 0.223
Fathers level of education
 No education 1
 Primary 3.053 0.85 10.961 0.087
 Secondary 2.878 0.75 11.045 0.124
 Tertiary 5.715 1.142 28.589 0.034
Mothers level of education
 No education 1
 Primary 1.201 0.344 4.197 0.774
 Secondary 0.733 0.184 2.921 0.66
 Tertiary 0.601 0.116 3.127 0.545
Fathers occupation
 Unemployed 1
 Unskilled 6.426 2.26 18.272 < 0.001
 Semiskilled 3.62 1.252 10.462 0.018
 Skilled 5.086 1.023 25.289 0.047
Mothers occupation
 Unemployed 1
 Unskilled 0.339 .1 1.151 0.083
 Semiskilled 0.333 0.088 1.27 0.107
 Skilled 1.48 0.133 16.482 0.75
Religion
 Christianity 1
 Islam 0.556 0.308 1.003 0.051
 Traditional 0.141 0.043 0.462 0.001

Bold p-values indicate statistical significance

Discussion

This study assessed the HPV vaccine knowledge, attitude and programme satisfaction among parents and caregivers of HPV vaccine recipients in Ogun State Nigeria, during the recent introduction of HPV vaccination into routine immunization. Over eighty percent of the respondents heard of HPV vaccine for the first time, during the HPV vaccination introduction program. Knowledge of HPV vaccination was high, all respondents had positive perception towards the HPV vaccine and cervical cancer, and programme satisfaction was high.

Most of the respondents had good knowledge of HPV vaccination. Most knew the benefit of HPV vaccination, majority knew that only one dose was required, and that girls aged 9 to 14 years were eligible to receive the vaccine. In a study in Meta Robi District, Oroma region, Ethiopia, few parents knew HPV vaccination protects against cervical cancer and only a few knew the age group eligible for the vaccine [21]. In Saudi Arabia, majority of the parents visiting a tertiary health facility did not know those who should receive HPV vaccination [22]. In both the Ethiopia and Saudi Arabia studies, HPV vaccination had been introduced 2 years and 12 years prior to the conduct of the studies respectively. Knowledge may be higher in our study due to ongoing awareness campaign efforts. Knowledge may have also been higher in our study because the study population was parents/caregivers of vaccine recipients, and not the general population. Adequate knowledge about vaccines is important to promote uptake, which could have contributing to the parents/caregivers immunizing their daughters in this study.

In our study, town/market announcers were the predominant source of information on HPV vaccination, as about forty percent had heard about the vaccine through this means. A higher proportion of rural dwellers heard about HPV vaccination from town/market announcers. Ogun State has many rural communities, and as such, this means can be effective in passing messages about vaccines. On the other hand, in a community-based cross-sectional study among parents in Debre Tabor Town, Ethiopia, the predominant source of information was radio/television and health extension workers [23]. Our study was carried out during vaccine introduction hence the use of town and market announcers is predominant, even in urban communities, as that was one of the communication strategies deployed.

Other major sources of information in this study include radio, social media, banners/posters and hospital/health center. Many studies among youth show that the predominant source of information on HPV vaccine is from schools, internet/social media and from friends [2426] and in a study among youth in Switzerland, school was by far, the predominant source of information [25]. Radio was a more common means of information than television in our study, unlike a study conducted among parents in the United States [27]. This may be because in Nigeria, many use battery charged radios for entertainment as televisions can only be powered by electricity which’s supply is poor, coupled with the recent increase in the cost of petrol to power generators in homes.

Attitude towards the vaccine was good for all the respondents which is not surprising, as they had immunized their wards. Even though more than ninety percent of respondents had heard messages aimed at discouraging parents from immunizing their wards, all the respondents had positive attitude towards the vaccine. Positive attitude, just like adequate knowledge has also been found to improve uptake of vaccines [28, 29].

In our study, the predominant reason parents chose to immunize their wards was to prevent cervical cancer. In a study carried out in Serbia, to prevent cancers was also a top-ranking motive to vaccinate one’s child [30]. Other predominant reasons given by parents/caregivers for taking the vaccine for their wards in the current study, center around the fact that there were ongoing awareness activities in communities—“they heard about the vaccine and felt their ward should have it”; the vaccines were readily available without having to go the health facility—“there was a campaign”; and because it was free. This goes to show the importance of awareness generation activities, accessibility and affordability of vaccines in promoting uptake. In a study in the United States, the greatest motive of parents for vaccinating their child was advice by a paediatrician [31]. This was the fifth most common reason in our study, accounting for 18% of responses. In Nigeria, children don’t have routine check-up visits to paediatricians or to the health facility, hence contact with health workers may be limited. This may be responsible for fewer parents in our study vaccinating their wards for this reason.

High programme satisfaction may also have influenced parents/caregivers decisions to immunize their wards, as most had a positive perception of—competence of vaccinators, social mobilization efforts, cleanliness of the vaccination procedures, and were satisfied with the overall programme. Programme satisfaction is an important factor driving utilization of health services [3234]. Governments and health authorities should strive to improve all aspects of vaccine introduction programmes, to promote high satisfaction, which would likely increase vaccine uptake.

We collected data on exposure to HPV vaccination discouraging messages. Over ninety percent of respondents had heard messages discouraging HPV vaccination. Sixty-eight percent of respondents heard such messages via WhatsApp, even though only about thirty percent heard of HPV vaccine via social media. This may be because e-fliers and WhatsApp audio jingles were only available about two months to the immunization dates, leaving room for spread of misinformation and the need to extend the campaign dates by an extra month. WhatsApp voice notes containing vaccine misinformation also spread rapidly at about the same time in English and the local languages. Timely dissemination of correct information on vaccines is needed to mitigate against vaccine misinformation and disinformation. Even though we did not ask further questions on why the respondents still immunized their children, despite the discouraging messages, respondents immunized their wards majorly because the vaccine prevents cervical cancer, there was a campaign, and services were free. Further qualitative studies are needed to explore why some parents still immunize their wards despite hearing discouraging messages, and how they determine their source of truth.

Most of the respondents in our study were mothers of the vaccinated girls. Mothers with skilled occupation had higher knowledge of HPV vaccine and cervical cancer. Women in skilled occupations are likely to be more enlightened, hence their higher knowledge. Our study found that rural residents had higher knowledge of HPV vaccine. We also found that rural residents were more likely to hear about HPV vaccine from town/market announcers. This finding suggests that the use of town/market announcers may be adequate to provide basic information on eligibility for the vaccine, number of doses and benefit of the vaccine, which were the knowledge items assessed in this study.

Implications for policy and practice

Knowledge of HPV vaccine was high in our study, possibly because many parents of the vaccinated girls had secondary or tertiary education. It is important for government and non-governmental organizations, and ministries of health to intensify health education and health promotion activities among less educated population to further improve uptake of the vaccine. Continuous education of the populace is also needed to sustain the gains in knowledge of HPV vaccine.

Ministries of health, at district and state level, should encourage the use of mobile outreaches, targeting schools and communities from time to time, and not just rely on facility-based HPV immunization, as this was a motivator for vaccination reported in our study. Ministries of health, non-Governmental organizations and relevant agencies should ensure timely dissemination of information on vaccines. It is important for Governments and relevant health authorities to strive to improve all aspects of the HPV vaccination introduction programme as high satisfaction with the programme can positively influence uptake of the vaccine.

Strengths and limitations of the study

This study was carried out during the introduction phase of HPV vaccination into routine immunization in Nigeria. To the best of our knowledge, this is the first of such studies assessing programme satisfaction, vaccine knowledge and attitude, reasons for vaccination and sources of vaccine information among parents/caregivers of HPV vaccine recipients in Nigeria. The large sample size of this study and the widespread data collection in both rural and urban communities, and in all 20 LGAs, enhances its generalizability in the region where the study was conducted. This study however does not explore the knowledge, attitude and programme satisfaction among parents/caregivers of adolescents who were not vaccinated. Future studies are planned to achieve this. Responses could also be prone to social desirability bias as data collection was done at the vaccination sites. Also, due to the cross-sectional study design, causality cannot be inferred. Nevertheless, this study provides important information which are crucial for formative evaluation and planning of the next phase of HPV vaccine introduction in Nigeria.

Conclusion

Most of the respondents had good knowledge of HPV vaccination and less than half had good knowledge of cervical cancer. Town/market announcers was a good source of information on HPV vaccine, and also radio, social media, banners/posters. All respondents had good attitude towards the HPV vaccine despite hearing discouraging messages. Reasons for taking the HPV vaccine center around it protecting against cervical cancer, its availability, affordability and awareness, by reason of campaign and vaccine introduction activities. Most of the respondents were satisfied with programme. Discouraging messages were widely circulated via WhatsApp.

Ministries of Health can conduct campaign activities including outreaches and awareness generation activities to improve uptake of HPV vaccination. The use of WhatsApp as a platform to improve awareness and provide accurate information about the HPV vaccine could be intensified, in a bid to tackle/prevent misinformation in subsequent campaigns. Further studies can explore vaccine accepters motivation factors despite discouraging messages heard.

Supplementary Information

12978_2024_1913_MOESM1_ESM.xlsx (603.6KB, xlsx)

Additional file 1. Quantitative data on the Knowledge and Attitude towards HPV vaccine and programme satisfaction of HPV immunization introduction program in Ogun State, Nigeria

Acknowledgements

We are very grateful to the State Technical Facilitators, independent monitors, and the LGA monitoring teams (comprising of Medical Officers of Health, Local Immunization Officers, Health Educators, Monitoring and Evaluation officers, and Disease Surveillance and Notification Officers) who collected data for the study.

Abbreviations

ASIR

Age-standardized incidence rate

ASMR

Age-standardized mortality rate

GAVI

The vaccine alliance

HPV

Human papillomavirus

LGA

Local government area

LMIC

Low- and middle-income country

VR

Vaccine recipient

Author contributions

TO and EAO conceptualized the study. TO and EAO had the primary responsibility of designing of the study protocol. JOO, KO, SBS, TOO, CCA, OTI were involved in data collection. TO conducted the data analysis. SAO, WAE, OAR, AOT, TS, OBO, were involved in data and result interpretation. TO wrote the first draft of the manuscript. EAO and MOC provided oversight for the stages of the research. MRB, OOO and AB-T provided critical input in manuscript writing. All authors reviewed the manuscript and have read and approved the final manuscript.

Funding

Ogun State Primary Health Care Development Board.

Availability of data and materials

All data generated or analysed during this study are included in this published article [and its supplementary information files].

Declarations

Ethics approval and consent to participate

Ethical approval was obtained from Ogun State Health Research Ethical Review Committee (Approval Number: OGHREC/467/190). Written informed consent was obtained from all participants and participants were not coerced. All data from the study were handled with confidentiality.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Bruni L, Albero G, Rowley J, Alemany L, Arbyn M, Giuliano AR, et al. Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis. Lancet Glob Health. 2023;11:e1345–62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141:664–70. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Hull R, Mbele M, Makhafola T, Hicks C, Wang SM, Reis RM, et al. Cervical cancer in low and middle income countries (Review). Oncol Lett. 2020;20:2058–74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.WHO Regional Office for Africa. 2023. Available from: https://www.afro.who.int/health-topics/cancer (Accessed 08/09/2023)
  • 5.ICO/IARC Information Centre. Nigeria—Key data on HPV and HPV-related cancers. 2023 Available from: https://hpvcentre.net/statistics/reports/NGA_FS.pdf (Accessed 08/09/2023).
  • 6.National Cancer Institute. Human Papillomavirus (HPV) Vaccines. 2019. Available from: https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-vaccine-fact-sheet (Accessed 08/09/2023).
  • 7.Markowitz LE, Tsu V, Deeks SL, Cubie H, Wang SA, Vicari AS, et al. Human papillomavirus vaccine introduction—the first five years. Vaccine. 2012;30(SUPPL. 5):F139–48. [DOI] [PubMed] [Google Scholar]
  • 8.Adejoro L. Nigeria to get HPV vaccine November—WHO [Internet]. Punch. 2023 Available from: https://punchng.com/nigeria-to-get-hpv-vaccine-november-who/ (Accessed 08/09/2023).
  • 9.Abujah R. Nigeria To Introduce HPV Vaccine, Routine Immunisation | Science Nigeria [Internet]. Punch. 2022. Available from: https://sciencenigeria.com/nigeria-to-introduce-hpv-vaccine-routine-immunisation/ (Accessed 08/09/2023).
  • 10.Amponsah-Dacosta E, Blose N, Nkwinika VV, Chepkurui V. Human papillomavirus vaccination in South Africa: programmatic challenges and opportunities for integration with other adolescent health services? Front Public Health. 2022;10. [DOI] [PMC free article] [PubMed]
  • 11.PATH. National Expanded Program on Immunization the. HPV Vaccination in Africa: Lessons Learned from a Pilot Program in Uganda. 2011. Available from: www.path.org/cervicalcancerhttps://media.path.org/documents/RH_hpv_lessons_learned_uganda.pdf (Accessed 12/09/2023).
  • 12.Ladner J, Besson MH, Hampshire R, Tapert L, Chirenje M, Saba J. Assessment of eight HPV vaccination programs implemented in lowest income countries. BMC Public Health. 2012;12. [DOI] [PMC free article] [PubMed]
  • 13.Ogunsola EA. Ogun State Primary Health Care Development Board, State Report On Human Papillomavirus Vaccine Introduction Held in 20 LGAs Of Ogun State Between 24t–28th October 2023.
  • 14.Goyal RC. Research methodology for health professionals. New Delhi: Jaypee Brothers Medical Publishers; 2013. [Google Scholar]
  • 15.Akinleye HW, Kanma-Okafor OJ, Okafor IP, Odeyemi KA. Parental willingness to vaccinate adolescent daughters against human papilloma virus for cervical cancer prevention in Western Nigeria. Pan Afr Med J. 2020;36:1–10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Ajah LO, Iyoke CA, Ezeonu PO, Ugwu GO, Onoh RC, Ibo CC. Association between knowledge of cervical cancer / screening and attitude of teachers to immunization of adolescent girls with human papilloma virus vaccine in Abakaliki, Nigeria. Am J Cancer Prev. 2015;3:8–12. [Google Scholar]
  • 17.Mukama T, Ndejjo R, Musabyimana A, Halage AA, Musoke D. Women’s knowledge and attitudes towards cervical cancer prevention: a cross sectional study in Eastern Uganda. BMC Womens Health. 2017;17:9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Olubodun T, Odukoya OO, Balogun MR. Knowledge, attitude and practice of cervical cancer prevention, among women residing in an Urban slum in Lagos, South West, Nigeria. Pan Afr Med J. 2019;32:130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Olubodun T, Balogun MR, Olowoselu OI, Emina VA, Ugwuowo UU, Ogundele OO, Kerry M, Charles-Eromosele TO, Olubodun AB. Cervical cancer knowledge, risk factors and screening practices among women residing in Urban Slums of Lagos, Southwest. Nigeria West Afr J Med. 2022;39(6):595–602. [PubMed] [Google Scholar]
  • 20.Aliu M, Okafor N, Aliu A, Olatubi M, Ademuyiwa G. Parental uptake of cervical cancer vaccine for their female adolescent in a city in Nigeria. Womens Health Bull. 2022;9:86–94. [Google Scholar]
  • 21.Humnesa H, Aboma M, Dida N, Abebe M. Knowledge and attitude regarding human papillomavirus vaccine and its associated factors among parents of daughters age between 9–14 years in central Ethiopia, 2021. J Public Health Afr. 2022;13:1–16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Tobaiqy MA, Mehdar SA, Altayeb TI, Saad TMAS. Parental knowledge, views, and perceptions of human papilloma virus infection and vaccination-cross-sectional descriptive study. J Family Med Prim Care. 2023;12:556–60. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Mihretie GN, Liyeh TM, Ayele AD, Belay HG, Yimer TS, Miskr AD. Knowledge and willingness of parents towards child girl HPV vaccination in Debre Tabor Town, Ethiopia: a community-based cross-sectional study. Reprod Health. 2022;19:1–12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Rosen BL, Shew ML, Zimet GD, Ding L, Mullins TLK, Kahn JA. Human papillomavirus vaccine sources of information and adolescents’ knowledge and perceptions. Glob Pediatr Health. 2017;4. [DOI] [PMC free article] [PubMed]
  • 25.Schwendener CL, Kiener LM, Jafflin K, Rouached S, Juillerat A, Meier V, et al. HPV vaccine awareness, knowledge and information sources among youth in Switzerland: a mixed methods study. BMJ Open. 2022;12:1–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Kim J. The relationship of health beliefs with information sources and HPV vaccine acceptance among young adults in Korea. Int J Environ Res Public Health. 2018;15:1–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Vu M, Berg CJ, Pham NHT, Tiro JA, Escoffery C, Spring B, et al. U.S. Vietnamese parents’ trusted sources of information and preferences for intervention messaging about HPV vaccination: a mixed methods study. PEC Innovation. 2023;3:100189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Ndasauka Y, Twabi HS, Kainja J, Gunde AM, Makhumula-Mtimuni C. Knowledge, attitudes and demographic drivers for COVID-19 vaccine hesitancy in Malawi. Sci Rep. 2024;14. [DOI] [PMC free article] [PubMed]
  • 29.Galadima AN, Zulkefli NAM, Said SM, Ahmad N. Factors influencing childhood immunisation uptake in Africa: a systematic review. BMC Public Health. 2021;21. [DOI] [PMC free article] [PubMed]
  • 30.Štrbac M, Vuković V, Pustahija T, Nikolić N, Rajčević S, Ilić S, et al. Motives and attitudes of parents toward HPV vaccination: Results from the initial period of HPV vaccine rollout in Serbia. PLoS ONE. 2023;18(7):e0287295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Victory M, Do TQN, Kuo YF, Rodriguez AM. Parental knowledge gaps and barriers for children receiving human papillomavirus vaccine in the Rio Grande Valley of Texas. Hum Vaccin Immunother. 2019;15:1678–87. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Mkperedem AA, Ogunlade P, Igbolekwu C, Arisukwu O, Afolabi AO, Adedayo RA. Healthcare service delivery perception among NHIS-HMO enrollees in Lagos hospitals. Humanit Soc Sci Commun. 2023;10. [DOI] [PMC free article] [PubMed]
  • 33.Musakwa NO, Bor J, Nattey C, Lönnermark E, Nyasulu P, Long L, et al. Perceived barriers to the uptake of health services among first-year university students in Johannesburg, South Africa. PLoS ONE. 2021;16:e0245427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Onyeneho NG, Amazigo U V., Njepuome NA, Nwaorgu OC, Okeibunor JC. Perception and utilization of public health services in Southeast Nigeria: implication for health care in communities with different degrees of urbanization. Int J Equity Health. 2016;15. [DOI] [PMC free article] [PubMed]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

12978_2024_1913_MOESM1_ESM.xlsx (603.6KB, xlsx)

Additional file 1. Quantitative data on the Knowledge and Attitude towards HPV vaccine and programme satisfaction of HPV immunization introduction program in Ogun State, Nigeria

Data Availability Statement

All data generated or analysed during this study are included in this published article [and its supplementary information files].


Articles from Reproductive Health are provided here courtesy of BMC

RESOURCES